PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15913932-1	2005	In the present study, we investigated the signal transduction pathways of expression of IL-6 in the desferrioxamine (DFX)-stimulated cochlear auditory cell line, HEI-OC1 cells.	Deferoxamine	100-115	interleukin 6	Homo sapiens	88-92	
15913932-1	2005	In the present study, we investigated the signal transduction pathways of expression of IL-6 in the desferrioxamine (DFX)-stimulated cochlear auditory cell line, HEI-OC1 cells.	Deferoxamine	117-120	interleukin 6	Homo sapiens	88-92	
15913932-3	2005	DFX significantly increased the production of IL-6 (P<0.05) and expression of IL-6 mRNA but did not affect TNF-alpha production.	Deferoxamine	0-3	interleukin 6	Homo sapiens	46-50	
15913932-3	2005	DFX significantly increased the production of IL-6 (P<0.05) and expression of IL-6 mRNA but did not affect TNF-alpha production.	Deferoxamine	0-3	interleukin 6	Homo sapiens	81-85	
15913932-5	2005	Increased IL-6 by DFX was significantly inhibited by p38 inhibitor, SB203580 (about 72% inhibition, P=0.027) but not ERK inhibitor, PD98059 or JNK inhibitor, SP600125.	Deferoxamine	18-21	interleukin 6	Homo sapiens	10-14	
15913932-8	2005	DFX also induced IL-6 production and HIF-1alpha expression in the inner ear.	Deferoxamine	0-3	interleukin 6	Homo sapiens	17-21	
15913932-9	2005	We demonstrated the regulatory effects of MAPK, HIF-1alpha, and NF-kappaB on DFX-induced IL-6 production in a HEI-OC1 for the first time.	Deferoxamine	77-80	interleukin 6	Homo sapiens	89-93	
15913932-10	2005	In conclusion, these data indicate that regulation of inflammatory cytokine IL-6 by DFX, through mimicking hypoxic conditions, might explain its beneficial effect in the treatment of hypoxia-induced inner ear diseases.	Deferoxamine	84-87	interleukin 6	Homo sapiens	76-80